Big ERP Capabilities on a Small Budget

When a five-person startup gets the first quote for a real medical device ERP, the typical reaction is sticker shock followed by a hunt for cheaper alternatives. QuickBooks plus a few spreadsheets. A generic small-business ERP with a med-device "module" bolted on. A homegrown system stitched together from Airtable and Google Sheets.

On day one, those alternatives look like they save 80% of the cost. By month eighteen, they've usually cost more than the system they replaced — and they're being replaced under duress, with a launch on the line.

The reason is that generic systems track inventory movements. Medical device regulations demand granular lot-level traceability, controlled documents, validated electronic signatures, and audit trails that survive scrutiny. None of that is core to a generic system. All of it has to be added — through customization, third-party plugins, or manual processes that scale terribly.

Walk forward eighteen months on a "cheap" ERP choice and add up what's actually been spent.

Customization for design controls, CAPA, lot traceability, supplier qualification, document control — all bolted on by consultants at $200-300 per hour. Late-stage documentation scrambles staffed by contract documentation specialists at premium rates. Validation cycles for every customization because the changes weren't built under design control. Backfilling traceability data into the new system when the old one gets replaced.

Then add the opportunity cost. Launches slipping because the system can't produce the reports a 510(k) submission requires. Hospital quality audits failing because consignment inventory can't be reconciled. Sales deals stalling because RFP responses require evidence the system can't generate.

The original quote was 80% cheaper. The total cost of ownership ends up 30-50% higher than the purpose-built option would have been — and the team that has to live through the transition rarely forgets it.

Purpose-built medical device systems embed regulatory requirements into core business processes. Compliance becomes a natural outcome of normal operations rather than an expensive add-on. Operators don't have to remember to document — the act of working is the act of documenting. Quality doesn't have to chase down evidence — it's already structured and indexed.

That changes the math in three ways. First, day-to-day operating cost goes down because nobody is doing duplicate work. Second, audit preparation cost goes down because evidence is always assembled. Third, system replacement cost goes to zero because the system you choose pre-approval still works after you scale to commercial production.

If you're a founder or operations lead trying to justify a purpose-built system to a budget-conscious board, frame the comparison correctly. Don't compare license costs — those are the smallest line. Compare total cost of ownership over five years, with realistic assumptions about scale.

Include the cost of validation work. Include the cost of customization to add the modules a generic system lacks. Include the cost of the migration project you'll do in year three when the generic system can't keep up. Include the cost of the FDA observation that costs you a quarter of launches.

When those numbers are on the page, the "expensive" option usually becomes the obvious one. The trick is doing the math honestly before the cheaper system is already installed.

There are real options that combine medical-device-grade capabilities with pricing that's accessible to early-stage and SME manufacturers. Look for:

• Modular pricing — pay for the modules you need today, add the rest as you scale
• Standard MedTech features included, not sold as expensive add-ons
• Implementation teams with actual FDA submission experience
• Configuration over customization — the system flexes without writing code
• A clear path from pre-revenue to commercial scale without a rip-and-replace

Budget-conscious doesn't have to mean compliance-compromised. It means choosing the option whose total cost over the next five years is the lowest — not the option whose first invoice is the smallest. For medical device manufacturers, those two are rarely the same answer.